SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Several of the Union Republics themselves, most notably Russia, were further subdivided into Autonomous Soviet Socialist Republics (ASSRs). Though administratively part of their respective Union Republics, ASSRs were also established based on ethnic/cultural lines. On April 3, 1990, a law was passed which stated that when a union republic was voting to leave the Soviet Union, autonomous republics, autonomous oblasts, and autonomous okrugs had the right, by means of a referendum, to independently resolve whether they would stay in the USSR or leave with the seceding union republic, as well as broader rights to raise the issue of their state-legal status.
This can be especially beneficial in regions with high electrical conductivity or salt content in their water source. This could potentially avoid costly reverse osmosis filtration systems while maintaining high crop yield.
Imaging compounds, notably Pittsburgh compound B, (6-OH-BTA-1, a thioflavin), can selectively bind to amyloid beta in vitro and in vivo. This technique, combined with PET imaging, is used to image areas of plaque deposits in those with Alzheimer's.
Sources: en.wikipedia.org
=== Second and third nucleotide recognition === The second and third position nucleotides are recognized by YxxCxxxF and GTS sites. This process is very important because this gives eRF1 the ability to discriminate the stop codon from a uracil starting sense codons that codes for an amino acid. For example the cysteine amino acid is coded by the codon UGU. The first step in discriminating stop from sense codons is to distinguish purines from pyrimidines, since all stop codons have purine nucleotides in the +2 and +3 position. Two highly conserved amino acid residues Glu55 and Tyr125 (located in the YxxCxxxF motif) work in tandem to hydrogen bond with the N6 nitrogen atom on the adenosine/guanine nucleotide. This interaction excludes the possibility of pyrimidines in the +2 and +3 position. Further discrimination of the purines in the +2 and +3 position is need since UGG is a sense codon for tryptophan. In the case of UGG, the Glu55 residue is repelled from the strong negative charge from the two guanine nucleotides. Since no extensive hydrogen bonding occurred, the codon is not recognized as a stop codon. A very important residue in eRF1 is the Cys127 in the YxxCxxxF motif, which forms 2 hydrogen bonds with a Watson and Crick's edge located on the mRNA. The hydrogen bonding allows further stability of the eRF1-stop codon complex in multiple orientations and allows stacking/hydrogen bonding of the +2 and +3 position of the stop codon. The strength and number of the stacks on the second and third position allows eRF1 to discriminate stop codons from sense codons.
Dionex Corporation is an American company based in Sunnyvale, California. It develops, manufactures, sells, and services analytical chromatography systems for separating, isolating, and identifying the components of chemical mixtures. Such equipment is used in pharmaceutical manufacturing, medical research, environmental monitoring, and food testing. In December 2010 Thermo Fisher Scientific announced its acquisition of Dionex for $2.1 billion.
=== Health care === Albany is served by Samaritan Albany General Hospital, a 76-bed medical facility that is the main hospital for the city and has been in operation since 1924. Albany is also served by Samaritan North Albany Urgent Care and Geary Street Urgent Care, both of which are part of Samaritan Health Services. The unaffiliated Albany Family & Specialty Medicine also provides medical services to the community.
=== Diet === Diet is a critical component of treatment and is in some cases effective on its own following treatment with insulin. For example, a recent mini-study showed that many diabetic cats stopped needing insulin after changing to a low carbohydrate diet. The rationale is that a low-carbohydrate diet reduces the amount of insulin needed and keeps the variation in blood sugar low and easier to predict. Additionally, research indicates that feeding cats low-carbohydrate meals increases their chances of obtaining diabetic remission by four times. Also, fats and proteins are metabolized slower than carbohydrates, reducing dangerous blood sugar peaks right after meals. Cats are obligate carnivores and must consume meat to survive, as their bodies are unable to produce certain amino acids such as taurine and arginine, and cannot process many of the nutrients that meat has from other dietary sources. It is recommended to see a veterinary professional to discuss the specific dietary needs a cat with diabetes needs to manage their diabetes while also ensuring they do not develop other health issues related to malnutrition.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.